AbbVie Inc. (NEO:ABBV)

Market Cap	547.24B
Revenue (ttm)	83.08B
Net Income (ttm)	3.27B
Shares Out	n/a
EPS (ttm)	1.84
PE Ratio	167.33
Forward PE	16.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,981
Average Volume	16,260
Open	30.83
Previous Close	30.75
Day's Range	30.73 - 31.08
52-Week Range	23.68 - 34.48
Beta	0.51
RSI	43.80
Earnings Date	Oct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD